Sermorelin / GHRP-2 Blend
Also known as: Sermorelin & GHRP-2, Sermorelin + GHRP-2 Blend
A research blend pairing the GHRH analog Sermorelin with the growth hormone-releasing peptide GHRP-2. The combination is studied for synergistic stimulation of endogenous growth hormone.
Last updated
Mechanism of Action
Sermorelin is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29) that binds the pituitary GHRH receptor to promote synthesis and release of growth hormone. GHRP-2 is a synthetic agonist of the GHS-R1a (ghrelin) receptor that triggers a distinct GH pulse and suppresses somatostatin tone. Because the two peptides act on different receptors, their co-administration produces a synergistic, greater-than-additive GH release while preserving the natural pulsatile pattern of secretion.
- Half-life
- Mixed: Sermorelin ~10-20 minutes, GHRP-2 ~30-60 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for synergistic endogenous growth hormone release
- Investigated for improved lean body mass and recovery
- Examined for enhanced slow-wave sleep quality
- Researched for IGF-1 elevation via natural pituitary pathways
- Studied for support of fat metabolism and body composition
Potential Side Effects
- Injection-site irritation or transient swelling
- Increased hunger from GHRP-2 ghrelin-receptor activity
- Transient flushing or warmth after injection
- Mild water retention or tingling in extremities
- Possible mild rise in cortisol and prolactin
Common Dosing
Research-literature blends are studied at approximately 100-300 mcg of each component per administration, 1-3 times daily, often before sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy or history of cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to GHRH or GHRP analogs
Sermorelin / GHRP-6 Blend
A research blend combining the GHRH analog Sermorelin with the ghrelin-receptor agonist GHRP-6. It is studied for synergistic growth hormone release and appetite stimulation.
Sermorelin / Ipamorelin Blend
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
CJC-1295 (No DAC) / GHRP-2 Blend
This blend pairs CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-2, a growth hormone secretagogue, to synergistically stimulate pulsatile growth hormone release. Both are unapproved research peptides.
- View
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
1999
- View
GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers
1995
- View
Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature
1995
- View
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men
2009
- View
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
2006